Editas Medicine, once a high-flying biotechnology company with shares peaking at $71, has faced a significant decline, with its stock trading at $5.72 as of July 25, 2024. However, despite this drop, recent developments hint at a potential turnaround, although not without inherent risks. A Strategic Addition: Veteran CSO Joins Editas In a strategic move, … Continue reading Editas Medicine: From Decline to Potential Revival